Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
Read More
Lung Cancer
GEOMETRY Mono-1 Results: Capmatinib for the Treatment of MET Exon 14–Mutated NSCLC
Read More
Lung Cancer
Ramucirumab plus Erlotinib in the Treatment of Patients with NSCLC with EGFR Exon 19 or Exon 21 Mutations
Read More
Lung Cancer
First-Line Treatment with Lorlatinib Improves Outcomes Over Crizotinib in Patients with ALK-Positive NSCLC
Read More
Lung Cancer
Pralsetinib and Selpercatinib Evaluated as Treatment for Patients with RET Gene Fusion–Positive NSCLC
Read More
Lung Cancer
Trastuzumab Deruxtecan in Patients with HER2-Mutated Advanced NSCLC
Read More
Lung Cancer
ADJUVANT Study: Quality of Life with Adjuvant Gefitinib versus Vinorelbine plus Cisplatin in Patients with EGFR-Mutant NSCLC
Read More
Lung Cancer
Ensartinib in Crizotinib-Resistant, ALK-Positive NSCLC
Read More
Lung Cancer
Afatinib + Cetuximab versus Afatinib Alone for the First-Line Treatment of EGFR-Mutant NSCLC (SWOG S1403)
Read More
Lung Cancer
Afatinib in Asian and Non-Asian Patients with EGFR Mutation–Positive NSCLC Harboring Uncommon Mutations
Read More
1
2
3
Page 1 of 3
Results 1 - 10 of 30